Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.64 – $10.03
1% from low
Exchange
OTC Link
ADRC
Borrow rate
3.80%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.45B | $17.94B | $18.54B | $19.43B | $22.58B | $24.50B | $27.03B | $26.25B |
| Cost of revenue | $5.38B | $5.79B | $5.93B | $6.11B | $7.05B | $8.17B | $8.76B | $9.17B |
| Gross profit | $11.07B | $12.15B | $12.61B | $13.31B | $15.53B | $16.33B | $18.27B | $17.08B |
| Gross margin | 67.3% | 67.7% | 68.0% | 68.5% | 68.8% | 66.6% | 67.6% | 65.1% |
| R&D | $640.0M | $692.0M | $708.0M | $755.0M | $866.0M | $872.0M | $913.0M | $847.7M |
| Operating income | $5.09B | $5.16B | $5.85B | $6.36B | $6.44B | $6.77B | $7.32B | $7.14B |
| EBITDA | $5.68B | $5.68B | $6.35B | $7.08B | $7.23B | $7.73B | $8.48B | $7.85B |
| Net income | $3.85B | $3.87B | $4.20B | $4.83B | $4.71B | $4.78B | $5.05B | $3.42B |
| Net margin | 23.4% | 21.6% | 22.6% | 24.8% | 20.8% | 19.5% | 18.7% | 13.0% |
| EPS (diluted) | 1.81 | 1.82 | 1.97 | 2.26 | 2.21 | 2.22 | 2.25 | 1.52 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $29.5B | $2.56 | $2.49–$2.58 | 2 |
| 2027 | $31.5B | $2.73 | $2.67–$2.80 | 2 |
| 2028 | $33.5B | $2.97 | $2.93–$3.00 | 1 |
| 2029 | $35.9B | $3.33 | $3.29–$3.36 | 1 |
Forward consensus · source: Financial Modeling Prep
COLOPLAST AS SP/ADR
No one on the platform currently holds CLPBY.
No tracked institution reports a position in CLPBY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-22 | $0.0777 | 2026-06-01 |
| 2025-12-08 | $0.2821 | 2025-12-19 |
| 2025-05-16 | $0.0752 | 2025-05-22 |
| 2024-12-09 | $0.2391 | 2024-12-20 |
| 2024-05-17 | $0.0726 | 2024-05-28 |
| 2023-12-08 | $0.2310 | 2023-12-22 |
No one on the platform has traded CLPBY yet.
| $21.0B |
| — |
| SBHMYSino Biopharmaceutical Limited | $12.68 | +0.00% | $11.3B | — |
| SDMHFSartorius Stedim Biotech S.A. | $200.02 | -1.90% | $19.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.8× earnings vs its 5.7× historical median P/E.
Fair value ≈ $11.49 · price $5.70 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.